411 INNATE: immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses

福克斯 医学 结直肠癌 肿瘤科 放射治疗 化疗 癌症 内科学 新辅助治疗 临床试验 免疫疗法 外科 乳腺癌 奥沙利铂
作者
Nina N. Sanford,Eslam A. Elghonaimy,Adel Kardosh,Syed Mohammad Ali Kazmi,Javier Salgado Pogacnik,Xiaodong Yang,Robert Timmerman,Todd A. Aguilera
标识
DOI:10.1136/jitc-2021-sitc2021.411
摘要

Background

The relative risk of developing rectal cancer has quadrupled in young adults over the last 40 years and approximately 50% of patients develop recurrence within 3 years. Thus, there is a critical need for new approaches to improve survival but cancer Immunotherapy has had little impact on colorectal cancer. The anti-CD40 agonist immunotherapy is emerging and APX005M has shown promise in phase I and ongoing phase II trials. Anti-CD40 can stimulate both innate and adaptive immune responses and a greater response can be achieved combining anti-CD40 with radiation therapy (RT) in animal models. We developed the INNATE trial, a phase II randomized trial of neoadjuvant short course RT followed by chemotherapy with or without the addition of APX005M for rectal cancer (NCT04130854).

Methods

The INNATE trial is a multi-center, 58 patient, 3:2 randomization clinical trial, that adds APX005M to short course RT (SCRT) and subsequent FOLFOX chemotherapy prior to definitive radiation. Eligibility includes stage III and high risk stage II rectal cancer and candidates for standard neoadjuvant therapy and no contraindications for immunotherapy or radiation. Patients receive 5Gy x 5 fractions over five days and if randomized to experimental arm will receive APX005M on day 3 of radiation. After a two week break patients receive an optional endoscopy and biopsy followed by standard FOLFOX chemotherapy with APX005M infusion after disconnection of 5-FU chemotherapy pump. Study arm receives APX005M with 5 of 6 cycles of FOLFOX. After treatment patients undergo restating, endoscopy, and trans abdominal resection. The primary endpoint is pathologic complete response with the null estimated to be 20% and alternative 50% for a power of 0.8 and type 1 error of 0.1. Secondary endpoints include overall survival, toxicity analysis, and disease free survival. For correlative analysis, tissue is collected pre-treatment, two weeks after RT, and at surgery, then blood collected during treatment and at follow up.

Results

To date 16 patients have been randomized and initiated treatment. The treatment is well tolerated. Fiveteen patients received pre- and post-SCRT biopsies. The study team plans correlative analysis including single cell RNA sequencing, multiplex imunohistochemistry, and bulk sequencing. Preliminary data shows changes in the immune tumor microenvironment from patients treated as their own control and between SCRT versus SCRT + APX00M.

Conclusions

The INNATE trial shows feasibility of incorporating novel immunotherapies with an emerging standard of care incorporating short course RT. It serves as an important platform for scientific and clinical investigation.

Trial Registration

Clinicaltrials

gov: NCT04130854

Ethics Approval

The clinical trial has institutional review board approval at the University of Texas Southwestern, Oregon Health and Sciences University, Wake Forest, and Moffitt. All patients have provided informed consent.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
腾腾腾完成签到,获得积分10
刚刚
4秒前
科研通AI5应助大橙子采纳,获得10
5秒前
Rubby应助科研通管家采纳,获得10
5秒前
5秒前
6秒前
传奇3应助科研通管家采纳,获得10
6秒前
6秒前
俏皮火完成签到 ,获得积分10
6秒前
一一一应助Bin_Liu采纳,获得10
6秒前
7秒前
啾啾啾完成签到,获得积分20
8秒前
Wang完成签到,获得积分10
9秒前
11秒前
啾啾啾发布了新的文献求助10
11秒前
CHSLN完成签到 ,获得积分10
12秒前
biofresh发布了新的文献求助30
12秒前
12秒前
13秒前
超级无敌奥特大王完成签到,获得积分10
13秒前
NexusExplorer应助小包子采纳,获得10
13秒前
努力向前看完成签到,获得积分10
15秒前
15秒前
15秒前
agnes完成签到,获得积分10
16秒前
失眠的向日葵完成签到 ,获得积分10
16秒前
大橙子发布了新的文献求助10
17秒前
19秒前
20秒前
qq完成签到,获得积分10
21秒前
王二哈完成签到,获得积分10
22秒前
行者无疆发布了新的文献求助10
23秒前
令散内方完成签到,获得积分10
23秒前
外向的雁玉完成签到,获得积分10
23秒前
慧灰huihui发布了新的文献求助10
24秒前
Ava应助Desire采纳,获得10
25秒前
量子星尘发布了新的文献求助10
28秒前
风信子完成签到,获得积分10
28秒前
小熊完成签到 ,获得积分10
30秒前
34秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022